Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) saw a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 5,580,000 shares, a decrease of 16.5% from the November 15th total of 6,680,000 shares. Based on an average daily volume of 828,800 shares, the short-interest ratio is currently 6.7 days.
Insider Transactions at Replimune Group
In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.80% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Replimune Group
Several hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its position in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the last quarter. Point72 DIFC Ltd bought a new position in shares of Replimune Group in the second quarter worth approximately $57,000. Arizona State Retirement System purchased a new stake in shares of Replimune Group during the second quarter valued at approximately $108,000. Quest Partners LLC increased its position in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after acquiring an additional 3,150 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in Replimune Group in the 3rd quarter worth approximately $133,000. 92.53% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Replimune Group
Replimune Group Trading Up 2.7 %
Shares of NASDAQ REPL opened at $12.55 on Monday. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The firm has a 50-day moving average of $12.19 and a 200 day moving average of $10.53. The stock has a market cap of $858.67 million, a P/E ratio of -4.11 and a beta of 1.26.
Replimune Group (NASDAQ:REPL – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, sell-side analysts expect that Replimune Group will post -2.91 EPS for the current fiscal year.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Read More
- Five stocks we like better than Replimune Group
- What Makes a Stock a Good Dividend Stock?
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- ETF Screener: Uses and Step-by-Step Guide
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.